Browse the evidence

Sustained high-protein diets (HPD) exceeding 1.5 g/kg/day, particularly when consumed by athletes and bodybuilders, induce glomerular hyperfiltration and progressive glomerulosclerosis, leading to a rapid decline in kidney function and potential end-stage kidney disease.

If you are an athlete or bodybuilder, consuming protein levels significantly above 1.6 g/kg/day (often 3-4 g/kg/day) does not build more muscle but may accelerate kidney damage, especially if you have any underlying kidney issues. Monitor your kidney function regularly and consider reducing protein intake to the 1.6 g/kg/day range to maximize muscle gains while minimizing renal risk.

GLP-1 receptor agonists (semaglutide, tirzepatide) are effective for weight loss in the general population but demonstrate attenuated efficacy and unclear safety profiles specifically in breast cancer patients, particularly those receiving endocrine therapy.

If you have breast cancer and are taking hormonal therapy (like aromatase inhibitors), GLP-1 drugs like Semaglutide or Tirzepatide will likely help you lose weight, but not as much as they do for people without cancer. You should expect roughly half the weight loss seen in the general population. Discuss this with your oncologist, as safety data in your specific group is still being gathered.

Duodenal mucosal ablation (DMR) significantly reduces HbA1c in patients with Type 2 Diabetes, particularly those with high fasting glucose or insulin-requiring disease, by targeting the proximal small bowel to mimic the metabolic effects of bariatric surgery.

If you have Type 2 Diabetes and struggle to control your blood sugar with diet and medication, especially if you require insulin or have high fasting glucose, ask your doctor about Duodenal Mucosal Resurfacing (DMR). This is a minimally invasive endoscopic procedure that ablates a small section of your small intestine to improve how your body handles glucose. It is not a weight-loss surgery, but it can significantly lower your HbA1c and potentially reduce or eliminate your need for insulin. While it is a one-time procedure, it carries risks like stricture formation, so it is best considered for patients who have not responded to other treatments.

Roux-en-Y gastric bypass (RYGB) induces significant remission of Type 2 Diabetes (T2DM) and Systemic Arterial Hypertension (SAH) in obese patients, largely through neuroendocrine mechanisms involving GLP-1 and bile acids, independent of or in addition to weight loss.

For obese patients with difficult-to-control diabetes or hypertension, Roux-en-Y gastric bypass is a highly effective treatment that can lead to disease remission. This benefit is driven by hormonal changes in the gut (GLP-1 and bile acids) that improve metabolic control, not just by weight loss. While lifestyle changes are the first line of defense, they often fail to sustain control, making surgery a viable option for eligible candidates.

The ketone body β-hydroxybutyrate (βHB) inhibits glucose-induced GLP-1 secretion in enteroendocrine cells, with human jejunal enteroids showing sensitivity at much lower doses (10 mM) than murine cell lines (100 mM).

This research suggests that high concentrations of ketone bodies in the gut can suppress the release of GLP-1, a hormone that helps manage blood sugar and signals fullness. While this is a laboratory finding using human gut cells, it implies that metabolic states with high local ketone production (such as during fasting or specific dietary patterns) might alter how your body responds to carbohydrates by reducing this specific hormonal signal.

GLP-1 receptor agonists (GLP-1RAs) do not increase the risk of adverse events compared to non-GLP-1RA antiobesity medications in patients who have undergone bariatric surgery.

If you have had bariatric surgery and are considering GLP-1 medications (like semaglutide or liraglutide) for weight regain, current data suggests they are not more likely to cause adverse events than older weight loss medications. However, the study notes that starting these medications more than 12 months after surgery is associated with a significantly lower risk of adverse events compared to starting them within the first year.

Tirzepatide is associated with a higher likelihood of gastrointestinal adverse events compared to other GLP-1 receptor agonists (semaglutide, dulaglutide, liraglutide, and exenatide).

If you take tirzepatide, expect gastrointestinal issues like nausea or vomiting more often than with other GLP-1 drugs. These are usually mild and go away, but they are the most common reason people stop the medication. Monitor your symptoms and report them.

Oral delivery of GLP-1 analogs (semaglutide, exenatide, dulaglutide) using liposomes containing tetraether lipids (TELs) and cell-penetrating peptides (CPPs) significantly increases cellular uptake in intestinal epithelial models compared to free peptides or conventional liposomes.

This research suggests a promising future where GLP-1 drugs (like Ozempic or Wegovy) could be taken orally using advanced liposome technology, potentially replacing injections. Currently, this is pre-clinical data showing high uptake in cell models, not a available product.

Acute L-arginine supplementation (6–8 g) taken 60–90 minutes before strength training provides no ergogenic effect on muscular endurance, peak torque, or resistance rate.

Do not take L-arginine specifically to boost your strength training performance. Taking 6-8 grams an hour before lifting does not increase your strength, endurance, or muscle growth compared to a placebo. While it may increase blood flow, this does not help you lift more weight or do more reps.

In patients with type 2 diabetes and baseline eGFR <80 mL/min/1.73 m2, intensive lifestyle intervention is associated with a slightly higher mean eGFR over 10 years compared to usual care, suggesting a potential benefit in preserving kidney function in this subgroup.

If your kidney function is already slightly reduced (eGFR <80), an intensive lifestyle program may help you maintain a slightly higher average kidney function level over 10 years compared to standard care. While it may not stop the decline entirely, it might offer a small protective benefit. Discuss this with your doctor to see if you are a candidate.

Compounded GLP-1 receptor agonists (semaglutide, tirzepatide) are widely marketed for weight loss in Colorado, but these products lack FDA approval for safety and efficacy, are often mislabeled as 'generic' or 'FDA-approved', and may contain unsafe additives like BPC-157 or unapproved salt forms.

Be aware that compounded GLP-1 drugs sold directly to consumers are not FDA-approved for safety or efficacy. They may contain impurities, incorrect doses, or unsafe additives like BPC-157. Marketing claims of 'FDA approval' or 'generic' status are misleading. Consult a healthcare provider to understand the risks and legal status of these products.

Subcutaneous administration of a semaglutide-rosuvastatin-lipid conjugate nanoparticle (SRLC NP) formulation significantly reduces body weight and improves liver function markers in high-fat diet-induced obese mice compared to conventional semaglutide or individual components.

This research describes a novel experimental nanoparticle formulation combining semaglutide with a statin-lipid conjugate. In obese mice, this specific formulation led to significant weight loss and liver health improvements compared to standard treatments. However, this is preclinical data; it is not a current treatment option for humans, and the safety and efficacy in people remain unproven.

Dihydromyricetin (DHM) supplementation improves insulin resistance and glucose tolerance in high-fat diet-induced mice by modulating gut microbiota to increase chenodeoxycholic acid (CDCA), which inhibits farnesoid X receptor (FXR) expression in intestinal L cells, thereby increasing glucagon gene (Gcg) mRNA expression and enhancing glucagon-like peptide-1 (GLP-1) secretion.

This research suggests that Dihydromyricetin (DHM), a compound found in plants like Ampelopsis grossedentata, may help improve insulin sensitivity and blood sugar control by changing gut bacteria to produce more beneficial bile acids (CDCA). This process boosts GLP-1, a hormone that helps regulate blood sugar. While this was shown in mice fed a high-fat diet, it points to the importance of gut health in metabolic function. For humans, this implies that dietary sources of DHM or gut-health-supporting strategies might be a complementary approach to managing insulin resistance, though human dosing and efficacy are not yet established.

Dysregulation of hypothalamic nuclei (specifically AgRP and POMC neurons in the arcuate nucleus) is a primary driver of obesity and type 2 diabetes through mechanisms involving insulin resistance, hyperphagia, and disrupted glucose sensing.

Metabolic diseases like obesity and diabetes are not just about willpower or peripheral fat storage; they involve critical signaling centers in the brain (the hypothalamus). When these signals (like leptin and insulin) are disrupted, it drives hunger and insulin resistance. This understanding supports the use of therapies that target these central pathways, such as GLP-1 receptor agonists, to help restore metabolic balance.

AgRP neuron hyperactivity contributes to chronic insulin resistance and obesity by inducing brown adipose tissue-derived myostatin expression, which systemically inhibits insulin signaling in skeletal muscle and white adipose tissue.

This mechanism explains why some individuals with obesity struggle with insulin resistance beyond just fat mass. It suggests that targeting the AgRP-myostatin pathway could be a therapeutic strategy, although current treatments focus more broadly on GLP-1 and MC4R pathways.

Tirzepatide reduces MC38 colon tumor growth rates in diet-induced obese mice by approximately 50%, but this effect is indirect and mediated by reduced food intake, lower insulin, and lower leptin levels rather than direct anti-proliferative action on cancer cells.

For obese individuals with early-stage, insulin-sensitive cancers (like colon cancer), tirzepatide may help slow tumor growth. This benefit appears to come from reducing insulin and leptin levels through weight loss and appetite suppression, not from directly attacking the cancer cells. It is not a cure, but it may improve outcomes by altering the metabolic environment that fuels cancer growth.

Ingestion of an isonitrogenous non-essential amino acid (NEAA) formulation does not stimulate muscle protein synthesis (MPS) or activate mTOR signaling pathways in skeletal muscle cells, making it an effective non-bioactive control for protein bioactivity studies.

If you are looking to stimulate muscle growth, consuming non-essential amino acids (NEAA) alone will not trigger the necessary biological signals. Muscle protein synthesis is driven by essential amino acids (EAAs), specifically leucine. Use NEAA as a control or filler in studies, but rely on complete proteins or EAAs for actual muscle building effects.

A two-meals-a-day ketogenic diet may cause an increase in serum uric acid levels in patients with type 2 diabetes.

Monitor uric acid levels when starting this diet, as it may rise. This is a known trade-off of ketosis.

Semaglutide 2.4 mg use is associated with significant side effects, including gastrointestinal distress and rare but severe complications like pancreatitis.

Be prepared for gastrointestinal side effects, especially when starting or increasing the dose. These often subside, but severe symptoms like pancreatitis require immediate medical attention.

Baseline gut microbiome composition predicts the efficacy of semaglutide and empagliflozin in reducing HbA1c, whereas the drugs themselves do not significantly alter microbial diversity or composition.

If you are starting semaglutide or empagliflozin for Type 2 Diabetes, your current gut bacteria might predict how much your blood sugar (HbA1c) will drop. The drugs themselves don't seem to drastically change your gut diversity, but knowing your baseline microbiome could help personalize your treatment. This is still early research, so discuss testing options with your doctor.

Phentermine is generally avoided in older adults due to risks of falls, anxiety exacerbation, and cardiovascular side effects, despite its efficacy in younger populations.

Phentermine is rarely recommended for older adults because it can cause dizziness (increasing fall risk), worsen anxiety, and strain the heart. It is generally avoided in this age group due to multiple comorbidities.

GLP-1 agonist pharmacotherapy for obesity in women may not be economically justified by healthcare cost savings alone, as the high lifetime cost of obesity is largely driven by reduced life expectancy rather than increased annual healthcare utilization.

For women with obesity, using GLP-1 medications like semaglutide or tirzepatide is a significant financial investment. Current economic models suggest that simply saving on annual medical bills for obesity-related conditions may not cover the drug costs. However, if the treatment successfully extends life expectancy by even 50% of the years lost to obesity, the long-term value to the healthcare system and the patient's quality of life can justify the expense.

DJB implantation leads to significant improvements in liver enzymes (AST, ALT, GGT) and lipid panels (LDL, Cholesterol, HDL, TAG).

DJB implantation improves liver health (reducing enzymes like AST and ALT) and improves lipid profiles (lowering bad cholesterol and triglycerides, raising good cholesterol).

Nanomedicine delivery systems can enhance the efficacy of glucose-lowering drugs by enabling site-specific delivery to macrophages, potentially inducing plaque regression.

This is currently a research area. While standard GLP-1 injections work, scientists are developing nanoparticle versions that might target heart plaques directly. This is not yet available for routine clinical use.